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Abstract Molecular chaperones assist protein fold-
ing, and variations in their encoding genes may be
disease-causing in themselves or influence the phe-
notypic expression of disease-associated or suscepti-
bility-conferring variations in many different genes.
We have screened three candidate patient groups for
variations in the HSPD1 and HSPE1 genes encoding
the mitochondrial Hsp60/Hsp10 chaperone complex:
two patients with multiple mitochondrial enzyme
deficiency, 61 sudden infant death syndrome cases
(MIM: #272120), and 60 patients presenting with
ethylmalonic aciduria carrying non-synonymous sus-
ceptibility variations in the ACADS gene (MIM:
*606885 and #201470). Besides previously reported
variations we detected six novel variations: two in the
bidirectional promoter region, and one synonymous
and three non-synonymous variations in the HSPD1
coding region. One of the non-synonymous variations
was polymorphic in patient and control samples, and
the rare variations were each only found in single
patients and absent in 100 control chromosomes.
Functional investigation of the effects of the varia-
tions in the promoter region and the non-synonymous
variations in the coding region indicated that none of
them had a significant impact. Taken together, our
data argue against the notion that the chaperonin
genes play a major role in the investigated diseases.
However, the described variations may represent
genetic modifiers with subtle effects.
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Introduction
In many monogenic diseases, the phenotype is not
solely determined by gene variations in the primary
target gene, but is subject to modification by so-called
modifier genes and environmental influences (Dipple
and McCabe 2000; Nadeau 2001). In complex multi-
factorial diseases, no single gene defect with a large
impact is present, but rather a set of gene variants (also
termed modifiers), each exerting a small effect in itself,
can act together with environmental factors to produce
the disease phenotype (Botstein and Risch 2003).
Modifying effects may be brought about by influenc-
ing the level of expression of a target gene product, its
intracellular trafficking and folding, posttranslational
modifications, activity and/or structural maintenance,
and turnover. Molecular chaperones assist and supervise
intracellular protein folding and are, together with spe-
cific proteases, involved in clearance of misfolded and
damaged proteins. They typically interact with a large
number of different proteins, and it has been proposed
that genetic variations in chaperone genes may function
as modifiers of amino acid substituting variations in-
volved in many traits/diseases (Slavotinek and Biesecker
2001). Genetic screens of neurodegenerative disease
models have indeed shown that molecular chaperones,
intracellular proteases and other components involved in
protein quality control represent a prominent group
of such modifier genes (Fernandez-Funez et al. 2000;
Bonini and Fortini 2003; Nollen et al. 2004). It has
furthermore been demonstrated that even a simple
decrease in the levels of the Hsp90 chaperone may
enable a number of otherwise suppressed phenotypic
traits to be expressed in natural fruitfly and Arabidopsis
populations (Rutherford and Lindquist 1998; Queitsch
et al. 2002). A similar buffering function against delete-
rious variations has also been accomplished by experi-
mentally increasing the levels of the bacterial GroEL/ES
chaperone complex (Fares et al. 2002).
The mammalian mitochondrial homolog of the bac-
terial GroEL/GroES chaperone system consists of
Hsp60 and Hsp10. It is involved in folding of a subset of
mitochondrial proteins (Dubaquie et al. 1998). Homo-
zygosity for deleterious mutations in the Drosophila
melanogaster gene encoding the fly Hsp60 homolog
causes death early in embryogenesis establishing that
Hsp60 is an essential protein (Perezgasga et al. 1999).
We have shown that knock-down of the HSPD1 gene
by RNAi in human cells compromises folding of the
mitochondrial matrix enzymes short-chain acyl-CoA
dehydrogenase (SCAD) and medium-chain acyl-CoA
dehydrogenase (MCAD), encoded by the ACADS
and ACADM genes respectively, and mitochondrially
targeted green fluorescent protein (Corydon et al.
2005). In addition, disease-causing mutant variants in
the medium- and short-chain acyl-CoA dehydrogenases
have been shown to remain in complex with the Hsp60
chaperonin for prolonged periods of time (Saijo et al.
1994; Pedersen et al. 2003), and elevated chaperonin
levels could partially rescue the correct folding of some
of them (Andresen et al. 2001; Bross et al. 1993, 1995).
We have recently reported the genomic structure of
the human chaperonin genes and variations in these
genes in a small set of independent control chromo-
somes (Hansen et al. 2003). Our genetic investigation
of a French family with an autosomal dominant form of
spastic paraplegia (SPG13; MIM 605280) identified a
missense mutation in the HSPD1 gene (c.292G>A/
p.Val98Ile) that segregated with the disease phenotype
and was shown to compromise chaperonin function
(Hansen et al. 2002).
To further extend the search for disease-associated
variations in the HSPD1/HSPE1 genes we have in the
present study screened three patient groups, in which
an involvement of the Hsp60/Hsp10 chaperonin system
has been indicated or suggested.
Primary disease gene group Two patients reported
with multiple mitochondrial enzyme deficiency
(Agsteribbe et al. 1993) who displayed decreased
activities of a number of mitochondrial metabolic
pathways; Hsp60 protein levels in cultured fibroblast
cells from one of these patients were shown to be
decreased (Briones et al. 1997) suggesting that a defect
in the Hsp60 chaperonin might cause deficient folding
of various enzymes involved in these pathways.
Modifier gene group Sixty patients presenting with
ethylmalonic aciduria who carried either of two
polymorphic SCAD missense variations conferring
susceptibility to SCAD deficiency (Corydon et al.
2001); although both variant SCAD proteins are
functional, they have been shown to cause prolonged
association of the variant SCAD proteins with the
Hsp60 chaperonin (Pedersen et al. 2003).
Genetic predisposition group Sixty-one cases of
sudden infant death syndrome (SIDS); RFLP analysis
has indicated overrepresentation of a certain HSPD1
genotype in a group of SIDS cases (Rahim et al. 1996),
and heat stress has been reported as risk factor for
SIDS (Byard and Krous 2003).
In these patients, we sequenced all exons, exon-intron
junctions and the bidirectional promoter region. The
frequencies of the detected variations were analysed in
control individuals, and functional analysis of potential
effects of variations in the promoter region on tran-
scription and of non-synonymous variations in the coding
region on in vivo chaperonin function was performed.
J Hum Genet (2007) 52:56–65 57
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Materials and methods
Patients
SIDS cases
The 61 patients included in the present study form part
of an extensive forensic material comprising cases of
sudden, unexpected death in infants and young chil-
dren (0–10 years old) that have been autopsied at the
Institute of Forensic Medicine, University of Aarhus,
in the years 1989–1998. A part of the samples has
previously been used in an investigation of the possible
relationship between fatty acid oxidation disorders and
sudden death in infancy (Lundemose et al. 1997). DNA
was purified from cultured primary fibroblast cells
isolated from Achilles tendon biopsies taken at the
autopsy. The ethical committee (Den Videnskabset-
iske Komite´ for A˚rhus Amt) has approved the use of
the SIDS material in the present study.
Patients with elevated urinary excretion of ethylmalonic
acid and presence of SCAD susceptibility variations
(hereafter called EMA/SCAD patients)
Patients referred to metabolic centres in Europe and
the USA that displayed elevated levels of ethylmalonic
acid in urine (>18 mmol/mol creatinine), and/or other
biochemical parameters indicating SCAD deficiency,
are routinely submitted to our laboratory for genetic
analysis. A large fraction of these patients carry the
polymorphic c.511C/T and/or c.625G/A variations in
the ACADS gene in both alleles or in combination with
rare, likely disease-causing mutations in the other al-
lele. The polymorphic variations are present in
homozygous or compound homozygous form in 14% of
the population but strongly over-represented in pa-
tients indicating that other factors contribute. Based on
the finding that interaction of the polymorphic SCAD
variant proteins with the Hsp60/Hsp10 chaperone sys-
tem had been shown to be altered (Pedersen et al.
2003), we investigated the HSPD1 and HSPE1 genes in
60 patients with the following ACADS genotypes (28
c.625A/c.625A, 2 c.625A/c.511T; 2 c.511T/c.511T, 24
c.625A/rare; 4 c.511T/rare).
Patients with multiple mitochondrial enzyme deficiency
(MMED)
These were two patients described previously (Briones
et al. 1997; Agsteribbe et al. 1993) in whom the activ-
ities of a series of mitochondrial enzymes were found
to be decreased. Both patients died of their disorder at
age 2 days and 4 1/2 years respectively. DNA purified
from cultured skin fibroblasts was analysed.
Control individuals
Twenty unrelated control individuals were selected
from the Danish Cell bank (Eiberg et al. 1983)
including the ten individuals reported earlier (Hansen
et al. 2003). To obtain a more precise estimate of the
frequencies for rare variations detected in the pro-
moter region (g.3172A>G, g.3191dupC, g.3198C>G)
and the amino acid replacing variations in the coding
region (c.1136A>G/p.Asp379Gly, c.1676G>A/p.Gly559p.
Asp, c.1688G>C/p.Gly563Ala), 30 additional, unre-
lated control individuals from the Danish Cell bank
were typed by sequencing the respective regions of the
genome. The frequencies for the c.292G>A/p.Val98Ile
variations associated with hereditary spastic paraplegia
and the c.551A>G (p.Asn184Ser) variation in 400
unrelated control individuals have been determined
previously (Hansen et al. 2002). For the polymorphic
variation c.1688G>C/p.Gly563Ala an additional 114
unrelated control individuals were typed using a PCR/
RFLP assay.
Sequencing
Screening for variations was performed by direct
sequencing in both directions (MMED patients) or one
direction (SIDS and SCAD/EMA patient groups) of
PCR products spanning exons or the promoter region
of the chaperonin genes as described previously
(Hansen et al. 2003). For ambiguous stretches in the
obtained sequences, amplification and sequencing was
repeated. Due to limited availability of material from
the SCAD/EMA patient group, repeating sequencing
of ambiguous regions was not possible in all cases, but
high quality sequences covered >95% of the sequenced
regions in this patient group. Sequences were aligned
using SEQUENCHER software (Version 3.1.1; Gene
Codes Corporation, Mich., USA) and the entire chro-
matograms were reviewed manually. The presence of
rare heterozygous variations was confirmed by
repeating PCR amplification and direct sequencing of
the respective region in the relevant samples.
Functional analysis of promoter variations
The detected promoter variations were introduced by
site-directed mutagenesis (QuikChange; Stratagene, La
Jolla, Calif., USA) into the two previously described
(Hansen et al. 2003) luciferase promoter reporter plas-
mids containing a 656-bp long fragment of the intergenic
58 J Hum Genet (2007) 52:56–65
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region between the HSPD1 and HSPE1 genes in either
orientation. The promoter inserts were sequenced to
verify the presence of the respective mutations and
thereafter subcloned into another batch of the pGL3
(Promega) parent vector to rule out nucleotide varia-
tions introduced into the vector region during the
mutagenesis procedure. Promoter activity was analysed
after co-transfection of the human embryonic kidney
cell line HEK-293 (ATCC) with the luciferase reporter
constructs and the CMV-ß-galactosidase vector con-
struct. HEK-293 cells were cultured at 37C with 5% (v/
v) CO2 in DMEM (Gibco) supplemented with 5% heat-
inactivated FCS, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin (Leo, Denmark). Cells were seeded in 12-
well plates 1 day prior to transfection. Each well re-
ceived 75 ng pGL3 vector and 25 ng ß-galactosidase and
carrier DNA (empty pcDNA3.1 vector; Invitrogen) to a
total amount of 1.5 lg DNA before treatment with
FuGENE6 transfection reagent (Roche Diagnostics).
Cells were harvested 48 h post transfection in 200 ll
lysis buffer (Tropix). Luciferase and ß-galactosidase
activity was measured using a MicroLumatPlus LB96V
luminometer (Berthold) in combination with the Luc-
screen (Applied Biosystems) and Galacto-light plus kits
(Tropix), respectively. Correction for transfection effi-
ciency was done by normalising the luciferase activity to
the ß-galactosidase activity.
Analysis of missense variations
The non-synonymous variations in the coding region
(c.1136A>G/Asp379Gly, c1676G>A/Gly559Asp, and
c.1688G>C/Gly563Ala) were introduced, by site-di-
rected mutagenesis (QuikChange or megaprimer PCR-
method), into the prokaryotic expression vector that
contains cDNA encoding Hsp10 and the processed
form of Hsp60 supplemented with a methionine initi-
ation codon as an operon under control of an IPTG-
inducible promoter (Hansen et al. 2002). Presence of
the respective variations and absence of mutagenesis-
induced PCR errors was established by sequencing and
subcloning. The resulting vectors were used in the ge-
netic complementation assay described previously
(Hansen et al. 2002; Richardson et al. 2001).
Results
Variations in the coding and promoter regions
of the HSPD1 and HSPE1 genes
Sequencing of all HSPD1 and HSPE1 exons, exon/
intron junctions and the common bidirectional promoter
was performed on DNA from the 61 SIDS cases, 60
SCAD/EMA patients and two patients with multiple
mitochondrial enzyme deficiency.
We found that the multiple mitochondrial enzyme
deficiency patient described by Briones et al. (1997)
was heterozygous for the rare g.3507T allele (formerly
named IR 453C>T; nomenclature of sequence varia-
tions follows the recommendations of the Human
Gene Variation Society (http://www.hgvs.org/mutno-
men/) and numbering is based on accession number
AJ250915) in the promoter region. This variation has
been detected previously in a control individual, and
functional analysis revealed no effect on promoter
activity (Hansen et al. 2003). This patient was homo-
zygous for the frequent variant (g.3175C) of the
g.3175C/G polymorphism (formerly described as IR
121C/G) whereas the MMED patient described by
Agsteribbe et al. (1993) was homozygous for the less
frequent allele (g.3175G) of the g.3175C/G polymor-
phism (formerly described as IR 121C/G). Both pa-
tients were homozygous for the more frequent alleles
of the silent variations in exons 2 and 3 (c.69T and
c.273A; Fig. 1). Taken together, this defies the notion
that mutations in the HSPD1 and HSPE1 promoter,
coding regions and exon/intron junctions cause the
phenotype.
Analysis of the SIDS and SCAD/EMA patients
revealed six novel variations (Fig. 1; Tables 1, 2),
namely two in the promoter region (g.3172A>G,
g.3191dupC) and four in the coding region (one silent:
c.27C>G and three amino acid replacing variations:
c.1136A>G/p.Asp379Gly, c.1676G>A/p.Gly559Asp,
c.1688G>C/p.Gly563Ala; amino acid numbering in this
article starts with the initiator methionine; as for Hsp60,
the first amino acid of the mature polypeptide corre-
sponding to alanine-27 has commonly been used). No
variations were detected in the exon/intron junctions.
With regard to the polymorphic variations, the
g.3175C/G variation in the promoter, the c.-15C/T
variation in the 5¢UTR of the HSPD1 transcript, and
the silent c.273G>A variation in the HSPD1 coding
region displayed similar frequencies in the patient and
control groups (Tables 1, 2). The silent c.69T variant in
the coding region was found to be considerably less
frequent (8%) in the 20 fully sequenced control indi-
viduals as compared to the patient groups (16.4% in
the SIDS and 19% in the SCAD/EMA group, respec-
tively). This variation is registered in the dbSNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/;
see Table 1) and frequencies of 8 and 22% in a mul-
tinational and Japanese population, respectively, have
been measured indicating that ethnic differences may
be the reason for the discrepancy. The SCAD/EMA
J Hum Genet (2007) 52:56–65 59
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patients represent a multinational group whereas the
SIDS cohort like the control material is mostly of
Danish descent.
With the exception of the polymorphic variation in
the coding region (c.1688G>C/p.Gly563Ala), all novel
variations detected in this study were only found in one
allele of a single patient and absent in the analysed
control individuals. The non-synonymous c.551A>G/
p.Asn184Ser variation present in one allele of the SIDS
cohort was earlier found in a patient with spastic
paraplegia, but was absent in affected family members
from the same kindred (Hansen et al. 2002). It was also
detected in 1 out of 800 alleles from 400 unrelated
Danish control individuals, and functional analysis
using a bacterial complementation system showed that
it had no significant effect.
The overall number of variations detected in our
studies in the HSPD1-HSPE1 gene region is 14
(Fig. 1). Three (g.3175C>G, g.3507C>T, c.-15C>T) of
the 14 nucleotide variations are localised in hyper-
mutable CpG dinucleotides. Of the 14 variations that
we have detected in the present and previous work in
c. -15C>T
c.27C>G*
c.69C>T
g.3198C>G
c.1136A>G*
p.Asp379Gly
3 4 5 6 7 8 9 10 11 122234 11
promoter
HSPD1HSPE1 c.1676G>A*p.Gly559Asp
c.1688G>C*
p.Gly563Alac.551A>Gp.Asn184Ser
c.292G>A
p.Val98Ile
g.3172A>G*
c.273G>A
g.3175G>C
g.3191dupC*
g.3507C>T
Fig. 1 Variations in the coding region of the HSPD1 and
HSPE1 chaperonin genes and the bidirectional promoter. The
exon and promoter regions are drawn to scale. The position of
introns and the direction of transcription of the genes are
indicated. Non-synonymous variations in the coding region are
indicated above and variations in the promoter and silent
variations in the coding region below the drawing. The mutation
associated with hereditary spastic paraplegia in a French kindred
is boxed with a stippled line. Polymorphic variations are shaded
in grey and novel variations detected in the present study are
marked with an asterisk. Numbering refers to the genomic and
cDNA sequence coordinates from accession number AJ250915
Table 1 Frequencies of variations in the HSPD1 gene in patient groups and controls: promoter and 5’UTRs
Variation Promoter 5¢ UTR
g.3172A>G* g.3175C>G g.3191dupC* g.3198C>G g.3507C>T c.-15C>T
SIDS 0/122
<0.8%
33/122
27%
0/122
<0.8%
0/122
<0.8%
0/122
<0.8%
20/122
16.4%
EMA/SCAD 1/120
0.8%
28/120
23%
1/120
0.8%
0/120
<0.8%
0/120
<0.8%
18/116
16%
Controls (fully sequenced ) 0/40
<2.5%
8/40
20%
0/40
<2.5%
1/40
2.5%
1/40
2.5%
3/20
15%
Frequency in extended control sample 0/100
<1%
25/100
25%
0/100
<1%
1/100
1%
–
Our dbSNP accession number ss65658187 ss65658181 ss65658188 ss65658182 ss65658183 ss65658184
accession numbers for the same variation
in dbSNP
rs1116734 rs3190642
rs3749095
rs13165
rs16874342
Nucleotide positions refer to accession number AJ250915 (genomic sequence) or the deduced cDNA sequence referring to the ‘A’ in
the ATG start codon as position 1. Variations newly detected in the present study are marked with an asterisk. The number of detected
variants per alleles studied and the allele frequencies in percent are given. For some variations, values including the 20 fully sequenced
controls and an additional number of control alleles, which were only typed or sequenced in the respective regions, are also given. All
variations were submitted to dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). Accession numbers from our submission (publicly available
starting with BUILD 127) and of previous submissions of the same variant sites are given
60 J Hum Genet (2007) 52:56–65
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altogether 326 chromosomes from patients and control
individuals, 5 had previously been reported to the
dbSNP database (see Tables 1, 2). Six non-synonymous
variations in the HSPD1 and HSPE1 coding region
reported in dbSNP have not been observed in any of
the 326 chromosomes that we have sequenced. A large
number of intron-less HSPD1 and HSPE1 pseudoge-
nes are present in the human genome (see http://
www.pseudogene.org and Hansen et al. 2003; Pochon
and Mach 1996) and some of the reported variations
likely arise from them. It is thus advisable to proceed
with caution when using this information, and validate
variations in the chaperonin genes by using PCR
primers situated in the intron regions.
Based on our sequencing data, the nucleotide
diversity in the patient groups is somewhat higher than
in the control group (Table 3). In general, the nucle-
otide diversity in the HSPD1 and HSPE1 coding re-
gion in the patient groups and controls is markedly
lower than the average gene diversity (1/346) obtained
by Cargill and coworkers by screening of 106 potential
disease related genes in 114 independent alleles
(Cargill et al. 1999). It is likely that the lower diversity
in the chaperonin genes reflects their high conservation
throughout evolution.
Investigation of the effect of the variations situated
in the promoter
The two newly detected variations (g.3172A>G,
g.3191dupC) and the previously reported polymorphic
g.3175C>G variation in the bidirectional promoter
region were analysed using a luciferase reporter assay
as described earlier (Hansen et al. 2003). The
g.3172A>G variant showed a tendency to slightly
increased basal promoter activity in the HSPD1
direction (Fig. 2), whereas the other two variants
displayed very similar basal promoter activity in both
directions.
Investigation of the effect of the non-synonymous
variations in the coding region
The three newly-detected non-synonymous variations
in the HSPD1 coding region (p.Asp379Gly,
p.Gly559Asp, and p.Gly563Ala) were analysed using
the Escherichia coli complementation system used
previously (Hansen et al. 2002). In brief, plasmids
carrying cDNA encoding the mature part of the
respective Hsp60 variant proteins together with the
Hsp10 co-chaperonin as an operon were transformed
Table 2 Frequencies of variations in the HSPD1 gene in patient groups and controls: coding region
Variation Coding region
c.27C>G*
silent
c.69C>T
silent
c.273G>A
silent
c.292G>A
p.Val98Ile
c.551A>G
p.Asn184Ser
c.1136A>G*
p.Asp379Gly
c.1676G>A*
p.Gly559Asp
c.1688G>C*
p.Gly563Ala
SIDS 0/122
<0.8%
20/122
16%
33/122
27%
0/122
<0.8%
1/122
0.8%
0/122
<0.8%
0/122
<0.8%
3/122
2.5%
EMA/SCAD (120) 1/120
0.8%
23/120
19%
28/120
23%
0/120
<0.8%
0/120
<0.8%
1/120
0.8%
1/120
0.9%
3/120
2.5%
Controls (40) 0/40
<2.5%
3/40
8%
8/40
20%
0/40
<2.5%
0/40
<2.5%
0/40
<2.5%
0/40
<2.5%
0/40
<2.5%
Frequency in extended
control sample
–
–
–
–
–
–
0/800
<0.125%
1/800
0.125%
0/100
<1%
0/100
<1%
3/228
1.3%
Our dbSNP accession
number
ss65658189 ss65658185 ss65658186 ss65658194 ss65658193 ss65658190 ss65658191 ss65658192
accession numbers for the
same variation in
dbSNP
rs11551349
rs17857718
rs17844973
Rs1050347
rs17849711
rs3175511
rs17849710
rs8539
See footnote to Table 1 for explanations
Table 3 Variation in the HSPD1 and HSPE1 genes and the bidirectional promoter in patient groups and controls
Groups (number of
alleles tested)
Coding region Promoter + 5¢ UTR
Total Non-synonymous
Variant
sites
Frequency
(variations/bp)
Variant
sites
Frequency
(variations/bp)
Variant
sites
Frequency
(variations/bp)
SIDS (122) 57 1/4,347 4 1/61,945 53 1/1,280
SCAD/EMA (120) 57 1/4,276 5 1/48,744 48 1/1,390
Controls (40) 11 1/7,385 0 <1/81,240 12 1/1,853
J Hum Genet (2007) 52:56–65 61
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into E. coli B174 cells. The endogenous groESL
chaperonin genes were subsequently deleted using
phage transduction and homologous recombination.
As the bacterial chaperonins are indispensable genes,
the ability of the respective expressed Hsp60 variant
protein together with wild type Hsp10 to support
growth of E. coli cells lacking the endogenous chap-
eronins was scored as a measure for its functional
capacity. All three variants were able to functionally
complement the deletion of the E. coli groESL genes
suggesting that none of the mutations exerts a major
effect on chaperonin function. Furthermore, no
apparent differences in growth characteristics at vari-
ous temperatures could be observed between the
transductants carrying plasmids encoding the different
Hsp60 variants as compared to transductants with the
plasmid encoding wild type Hsp60 (data not shown).
Discussion
Although molecular chaperones have been in focus for
more than two decades, and variations in their corre-
sponding genes have repeatedly been suggested as
potential modifiers in various disease processes, surpris-
ingly few studies have addressed variations in these genes
in humans. Recently, variations in the Hsp90alpha and
Hsp90beta genes in 73 Caucasians have been reported
(Passarino et al. 2003) and subsequent investigations of
their functional effects using a yeast-based assay system
revealed that the non-synonymous variant p.Gln488His
in the alpha-Hsp90 gene was severely defective
(MacLean et al. 2005). Altogether 14 variations in the
three highly inducible cytosolic Hsp70 genes HSP70-1,
HSP70-2 and HSP70-HOM have been described, and
some of them have been shown to be associated with
various diseases, such as rheumatoid arthritis, multiple
sclerosis, insulin-dependent diabetes mellitus and ageing
just to name a few (see Singh et al. 2004 and references
therein).
In the present study, we selected a spectrum of
diseases where it was indicated that variations in the
mitochondrial chaperonin genes could represent dis-
ease-associated or disease-modifying factors. In the
MMED patients, decreased activities of a series of
mitochondrial enzymes were observed. Detailed anal-
ysis of one patient showed low levels of Hsp60 protein
and a partial deficiency in Hsp60 was suggested as the
likely cause (Huckriede et al. 1995; Huckriede and
Agsteribbe 1994; Agsteribbe et al. 1993). Our
sequencing results of this patient revealed only poly-
morphic variations in the chaperonin gene coding,
intron/exon junction and promoter regions. The
patient reported by Briones et al. (1997) displayed
heterozygosity for the g.3507C>T variation in the
promoter. This variation has been reported previously,
and functional analysis of its impact for promoter
activity revealed no significant effect (Hansen et al.
pGL3
wt
g.3172A>G
g.3175C>G
g.3191dupC
0 0,1 0,2 0,3 0,4 0,500,10,20,3
HSPE1 direction HSPD1 direction
Fig. 2 Analysis of the effect of the detected variations on
activity of the bidirectional promoter. Luciferase reporter
plasmids carrying a 656 bp fragment comprising the bidirectional
promoter with the indicated promoter variations in both the
HSPD1 and HSPE1 orientation were, together with a plasmid
carrying a cytomegalo virus promoter driven ß-galactosidase
cDNA, used to transfect HEK-293 cells (see Materials and
methods for details). Cells were grown at 37C, harvested after
48 h and luciferase and ß-galactosidase activity were determined.
Triplicate transfections were performed with two different DNA
preparations of each construct. The quotient of the values
obtained from the luciferase and ß-galactosidase measurements
normalised to the wild type in the HSPD1 or HSPE1 direction,
respectively, are given. As the two data sets had equal variances,
the values from both series were combined and common
standard deviations (error bars) were calculated. ‘wt’ refers to
the sequence carrying the most frequent alleles in all variant
positions; the variants carry the indicated variant nucleotide in
relation to ‘wt’
62 J Hum Genet (2007) 52:56–65
123
2003), arguing against the notion that mutations in the
chaperonin genes play a role in these patients.
For the SCAD/EMA patient group, a modifying
effect of variations in the chaperonin genes on SCAD
enzyme folding was suggested by the observation that
the two non-synonymous polymorphic ACADS gene
variants c.511T and c.625A, which are strongly over-
represented in the patient group compared to controls
(Corydon et al. 1996; Corydon et al. 2001), cause
prolonged interaction of their encoded SCAD variant
proteins with the Hsp60 chaperone and delayed
folding and assembly to the active tetramer (Pedersen
et al. 2003). Variations in the chaperonin genes that
compromise their function or affect their expression
could possibly exacerbate this mild effect and trigger
disease. In 60 patients presenting with ethylmalonic
aciduria and carrying one of these two rare ACADS
variations in at least one allele, we detected two
variations in the HSPD1/HSPE1 promoter region
(g.3172A>G, g.3191dupC) and two non-synonymous
variations in the HSPD1 coding region (c.1136A>G/
p.Asp379Gly, c.1676G>A/p.Gly559Asp). These varia-
tions were found in one allele of single patients
each and could potentially explain the defect in these
patients. However, analysis of their potential effects
on expression or function revealed no significant
impact. Because, in addition, no significant over- or
under-representation of the polymorphic variations
in the mitochondrial chaperonin genes could be
observed, we conclude that variations in the mito-
chondrial chaperonin genes play no significant role in
the SCAD/EMA patient group.
Finally, in the SIDS cohort study, a possible link to
the mitochondrial chaperonin genes was suggested by
the finding that hyperthermia, which is known to
induce HSPD1 and HSPE1 transcription, represents a
risk factor (Gozal 1996). In the 61 SIDS cases investi-
gated there was no significant over- or under-repre-
sentation of polymorphic sequence variations. One
patient was heterozygous for the non-synonymous
c.551A>G/p.Asn184Ser variation. This variation has
been reported earlier, as has the functional analysis of
its p.Asn184Ser variant protein in a bacterial comple-
mentation assay, which showed no dramatic effect on
chaperonin function (Hansen et al. 2002). These results
suggest that HSPD1 and HSPE1 gene variations rep-
resent no significant factor for the development of
SIDS. The MspI RFLP observed with a HSPD1 cDNA
probe, and reported to be overrepresented in a SIDS
cohort (Rahim et al. 1996), most likely represents a
polymorphism that resides in a HSPD1 pseudogene,
since the MspI sites in this chromosome region pre-
dicted by the complete human genome sequence are
not compatible with the chromosomal DNA fragments
observed by these authors (data not shown). Further-
more, the statistical significance of the finding has been
challenged (Tanner et al. 1997).
The rare variations in the promoter region and
the non-synonymous variations in the coding region
detected in this report may still exert mild effects
contributing to the phenotype in a few patients. Only
for the g.3172A variant was a small increase of pro-
moter activity indicated experimentally. The facts that
the g.3172A>G variant site, like the g.3175G>C
g.3191dupC sites, is situated in a short sequence stretch
that is absent in the mouse and rat promoter sequences
(Hansen et al. 2003), and that all five so far detected
variations in the HSPD1/HSPE1 promoter region are
situated distantly from the heat-shock factor binding
elements and the CHOP binding motif involved in the
heat-shock response and a mitochondria-specific stress-
response, respectively (Zhao et al. 2002), argue against
a major impact of any of them.
Functional testing of the non-synonymous variations
in the coding region using the bacterial complemen-
tation assay that is capable of revealing dramatic
effects, such as the one exerted by the mutation
(c.292G>A; p. Val98Ile) associated with hereditary
spastic paraplegia (Hansen et al. 2002), showed no
detectable effect, arguing against them having a major
impact. Two of the newly detected variations that alter
amino acids in Hsp60 are localised in a stretch
encoding the Gly-Gly-Met iterations in the carboxy
terminus of the protein. Similar sequences are present
in the carboxy terminus of many, but not all, type I
chaperonins (Brocchieri and Karlin 2000). A four-fold
Gly-Gly-Met repeat region is present in E. coli GroEL
C-terminus. Its structure is not resolved in the X-ray
crystals suggesting a flexible conformation. Deletion of
the entire repeat region in GroEL has indicated that it
is dispensable, although deletion had some effect on
ATPase activity and the ability to suppress tempera-
ture-sensitive mutations (Mclennan et al. 1993).
Moreover, a recent study showed that replacement of
the methionine residues by alanine decelerated folding
of a mutant maltose binding protein (Tang et al. 2006).
The variant positions of the p.Asn184Ser and the
p.Asp379Gly variations correspond to lysine-160 and
glutamic acid-354 in E. coli GroEL, respectively. In the
E. coli GroEL structure, both residues are situated at
the outer surface of the ring structure. Inspection of
alignments shows that the mutated asparagine-184 is
not well conserved, but a negatively charged residue
at the position corresponding to aspartic acid-379 in
human Hsp60 is conserved in the large majority of
chaperonins.
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In summary, we have described a series of variations
in the HSPD1/HSPE1 promoter and coding regions
that may exert potential effects on chaperonin
expression and function. Although the detected varia-
tions do not play a major role in the disease groups
investigated, they may still represent modifiers with
subtle effects. Although variations in chaperone genes
have been used in a large number of association stud-
ies, studies on functional tests of the impact of these
variations have been reported very rarely. Clearly,
functional testing of variations that exert small effects
is difficult, and devising appropriate assay systems that
can reveal small effects presents a challenge for future
research in the field of multifactorial diseases and
modifier genes.
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